NASDAQ:MTEM Molecular Templates (MTEM) Stock Price, News & Analysis $0.0001 0.00 (-50.00%) As of 03:16 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Molecular Templates Stock (NASDAQ:MTEM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Molecular Templates alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$2.04Volume207 shsAverage Volume4.04 million shsMarket Capitalization$658.40P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Read More… Remove Ads Molecular Templates Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreMTEM MarketRank™: Molecular Templates scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Molecular Templates. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Templates is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Templates has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Molecular Templates' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MTEM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMolecular Templates does not currently pay a dividend.Dividend GrowthMolecular Templates does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.93 Short InterestThere is no current short interest data available for MTEM. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for MTEM on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Molecular Templates insiders have not sold or bought any company stock.Percentage Held by Insiders13.90% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Molecular Templates' insider trading history. Receive MTEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter. Email Address MTEM Stock News HeadlinesNasdaq to file Form 25-NSE with SEC to delist Molecular TemplatesDecember 20, 2024 | markets.businessinsider.comMolecular Templates, Inc. Faces Delisting from Nasdaq Due to Compliance IssuesDecember 19, 2024 | quiverquant.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 4, 2025 | Brownstone Research (Ad)Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing RulesDecember 19, 2024 | globenewswire.comMolecular Templates Announces Key Leadership TransitionDecember 4, 2024 | markets.businessinsider.comMolecular Templates, Inc. Receives Nasdaq Deficiency Notification for Reporting and Bid Price ComplianceDecember 2, 2024 | quiverquant.comMolecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price RequirementsDecember 2, 2024 | globenewswire.comWhy Molecular Templates (MTEM) Stock Is Down 77% TodayOctober 14, 2024 | benzinga.comSee More Headlines MTEM Stock Analysis - Frequently Asked Questions How have MTEM shares performed this year? Molecular Templates' stock was trading at $0.04 at the beginning of 2025. Since then, MTEM stock has decreased by 99.8% and is now trading at $0.0001. View the best growth stocks for 2025 here. How were Molecular Templates' earnings last quarter? Molecular Templates, Inc. (NASDAQ:MTEM) posted its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative trailing twelve-month return on equity of 260.50% and a negative net margin of 61.35%. When did Molecular Templates' stock split? Molecular Templates shares reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Molecular Templates? Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Molecular Templates own? Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/15/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MTEM CIK1183765 Webwww.mtem.com Phone(512) 869-1555Fax650-474-2529Employees260Year Founded2009Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,120,000.00 Net Margins-61.35% Pretax Margin-61.39% Return on Equity-260.50% Return on Assets-46.90% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual Sales$23.48 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book0.00Miscellaneous Outstanding Shares6,584,000Free Float5,669,000Market Cap$658.40 OptionableNo Data Beta1.22 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:MTEM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.